• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
Treat NMD Logo (Copyright)

TREAT-NMD

Advancing diagnosis, care and treatment for people with neuromuscular diseases around the world

Contact us

header-right

  • Home
  • Who We Are
    • About Us
    • Partnerships and Collaborations
    • Governance
    • Our Team
  • Who We Support
    • Patients
    • Clinicians / Researchers
    • Life Sciences Industry
  • What We Do
    • Advisory Committee for Therapeutics
    • The Global Registry Network
    • Core Datasets
    • Education
    • Post-Marketing Surveillance
  • Resources and Support
    • Neuromuscular Disease Information
    • Research Overview
    • Standards of Care & Family Guides
    • SOP Library
    • Social and Ethical Issues
  • Conference
    • Registration
    • Sponsorship Opportunities
    • Conference Programme
    • Sponsors of the TREAT-NMD 8th International Conference
    • Programme Committee
    • Abstracts
    • Venue
  • News & Events
    • News
    • TREAT-NMD Events
    • All Events
    • Submit an Event
    • Newsletter Sign-up
    • Contact Us

Becker muscular dystrophy

Home / Resources and Support / Neuromuscular Disease Information / Becker muscular dystrophy

What is Becker muscular dystrophy?

Becker muscular dystrophy (BMD) is a genetic condition that causes a weakness in the muscles that progresses over time leading to increasing disability. Caused by a mutation in the dystrophin gene, it is a disease closely related to Duchenne muscular dystrophy, although it is less common. The progression and severity of the disease can vary significantly from person to person.

What causes Becker muscular dystrophy?

BMD is a genetic condition where a mutation occurs in the dystrophin gene located on the X-chromosome. The genetic mutation results means less dystrophin protein is produced and/or the dystrophin protein is smaller, and only partially functional. Dystrophin is vital in maintaining the integrity of muscles, and these changes mean muscle fibres break down and muscles gradually weaken. As the dystrophin gene is on the X-chromosome, BMD almost only affects males (females have two X-chromosomes and so one can compensate for the faulty one). While females who have one affected gene usually won’t show symptoms, they can be carriers of the disease and, therefore, the disease may be passed onto their children. The mutation can also arise spontaneously and does so in up to a third of all cases.

What are the signs and symptoms of Becker muscular dystrophy?

The symptoms of BMD can be mild initially, presenting with a delay in learning to walk, muscle cramps after exercise or generally struggling with sports. Later, those in their teens or 20s, may begin to experience more difficulty running, climbing stairs, and getting up from the floor. As muscles weaken, symptoms may manifest in the shoulders and arms and individuals may have trouble lifting objects above waist level and/or lifting their arms above shoulder level. Muscles that are weakened are often enlarged in people with BMD, this is particularly noticeable in the calf muscles.

Some people with BMD may also have heart problems (such as cardiomyopathy) and this can occur at any age. In BMD, heart problems often do not cause any symptoms and can often be treated.

How does the disease progress?

Some people with BMD will eventually require a wheelchair, this is usually between the ages of 40 to 50 (but could also happen earlier with more rapidly progressing cases). On the other hand, there are people with BMD who never lose the ability to walk and live into their 70s or 80s.

 

 

 

 

Primary Sidebar

  • Resources and Support
  • Disease Information
    • Neuromuscular Disease Information
    • Becker muscular dystrophy
    • Charcot-Marie-Tooth
    • Congenital muscular dystrophy
    • Congenital myasthenic syndromes
    • Duchenne muscular dystrophy
    • Facioscapulohumeral muscular dystrophy
    • GNE myopathy
    • Limb girdle muscular dystrophy
    • Myotonic dystrophy
    • Myotubular and centronuclear myopathies
    • Spinal muscular atrophy
  • Research Overview
    • Research Overview
    • Gene Therapy Research
    • DMD
      • DMD
      • Gene Therapy for DMD
      • Mutation Specific Approaches
      • Drug Therapy
        • Anti Inflammatory Drugs
        • Treating Fibrosis and Oxidative Stress
        • Ways to Improve Muscle Quality and Strenghth
        • Drugs to Bloodflow to Muscle
        • Drugs to Upregulate Utrophin
      • Cell Therapy
  • Standards of Care & Family Guides
    • Care Guides
    • BMD Care
    • CM Care
    • CMD Care
    • DM Care
    • DMD Care
    • FSHD Care
    • LGMD Care
    • SMA Care
  • Standard Operating Procedures (SOPs)
    • SOP Library
    • MDX Mouse (DMD)
    • GRMD Dog (DMD)
    • CMD Mouse (CMD)
    • SMA Mouse (SMA)
    • SOP Archive
      • MDX mouse (DMD) Archive
      • SMA mouse (SMA) Archive
      • Mouse model (DMD) Archive
  • Social and Ethical issues
    • Social and Ethical Issues
    • Concerns Over Stem Cell Therapy for SMA Type 1 Children
    • Early Access to Medicines in Development
    • Ethical Questions

Footer

Contact us

4th Floor
The Catalyst
Newcastle upon Tyne
NE4 5TG
United Kingdom
info@treat-nmd.com

Links

Home
Who we are
What we do
Who we support
Resources & support
Connect with us
Privacy Policy
Cookies

Newsletter Sign Up

Sign up to our monthly newsletter

 
ISO 27001 Accreditation Logo

Connect

info@treat-nmd.com
TREAT NMD © 2025
Privacy Policy
Sitemap
STCS LTD

  • Home
  • Who We Are
    • About Us
    • Partnerships and Collaborations
    • Governance
    • Our Team
  • Who We Support
    • Patients
    • Clinicians / Researchers
    • Life Sciences Industry
  • What We Do
    • Advisory Committee for Therapeutics
      • Members of the Advisory Committee for Therapeutics
      • Take Part in TACT
      • Past Applicants
    • The Global Registry Network
      • Members of the Registry Network
    • Core Datasets
      • DM dataset
      • DMD dataset
      • FSHD dataset
      • LGMD
      • SMA
    • Education
      • Masterclasses and Events
      • Digital Resources
      • Endorsement of External Programmes
    • Post-Marketing Surveillance
  • Resources and Support
    • Neuromuscular Disease Information
      • Becker muscular dystrophy
      • Charcot-Marie-Tooth
      • Congenital muscular dystrophy
      • Congenital myasthenic syndromes
      • Duchenne muscular dystrophy
      • Facioscapulohumeral muscular dystrophy
      • GNE myopathy
      • Limb girdle muscular dystrophy
      • Myotonic dystrophy
      • Myotubular and centronuclear myopathies
      • Spinal muscular atrophy
    • Research Overview
      • DMD
        • Gene Therapy for DMD
        • Mutation Specific Approaches
        • Cell Therapy
        • Drug Therapy
    • Standards of Care & Family Guides
      • CM Care
      • CMD Care
      • DM Care
      • DMD Care
      • BMD Care
      • FSHD Care
      • SMA Care
    • SOP Library
      • MDX Mouse (DMD)
      • GRMD Dog (DMD)
      • CMD Mouse (CMD)
      • SMA Mouse (SMA)
      • CMD animal models
      • MDC1A Preclinical Research
      • Cell Lines
        • Clinical Outcome Measures
        • Functional Evaluation Tools
        • NMR (MRI/MRS) Imaging
        • Muscle Biopsy
    • Social and Ethical Issues
  • Conference
    • Registration
    • Sponsorship Opportunities
    • Conference Programme
    • Sponsors of the TREAT-NMD 8th International Conference
    • Programme Committee
    • Abstracts
    • Venue
  • News & Events
    • News
    • TREAT-NMD Events
    • All Events
    • Submit an Event
    • Newsletter Sign-up
    • Contact Us